PTX 11.15 Pernix Therapeutics Holdings Inc. $PTX Hit a 52 week high of 11.21 Closing the day 09:44 at 11.15 +0.10 +0.90% With a day low of 11.08 and a total volume of 42,759.
PTX Recent Posts: http://investorshangout.com/Pernix-Therapeuti...PTX-57271/
PTX Pernix Therapeutics Holdings Inc. Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
PGNX: 6.50 (-0.11), ICUI: 83.66 (-1.07), CDZI: 10.71 (+0.03), INSY: 38.61 (-1.04), PCMI: 8.82 (+0.02), PTX: 10.91 (-0.14), CYAN: 6.23 (+0.25), ACHN: 13.92 (-0.93), AGIO: 87.23 (+0.36), LIOX: 5.30 (-0.13), PLNR: 6.70 (-0.45)
Midday gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:45AM CST
FSM: 4.27 (-0.21), HEAR: 4.02 (+0.01), JRJC: 6.65 (-0.55), CVO: 1.76 (-0.15), AAOI: 12.23 (-0.09), UNIS: 3.02 (-0.02), HIIQ: 8.45 (-0.25), CYAN: 6.23 (+0.25), PTX: 10.91 (-0.14), TRMR: 2.87 (-0.07), PRKR: 1.08 (unch), SUMR: 2.87 (+0.07), VSLR: 12.00 (-0.33), RVP: 4.00 (-0.10), ASCMA: 52.00 (+0.69), ICUI: 83.66 (-1.07), CALL: 8.40 (-0.28), DMD: 5.43 (-0.27), AST: 3.96 (-0.07), ASEI: 44.21 (-0.56)
Pernix Therapeutics Holdings' (PTX) CEO Douglas Drysdale on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:46PM CST
PTX: 10.91 (-0.14)
Pernix Therapeutics ups revenues 72% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:15PM CST
PTX: 10.91 (-0.14)
Pernix Therapeutics Holdings (PTX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:55AM CST
PTX: 10.91 (-0.14)
Pernix Therapeutics misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:09AM CST
PTX: 10.91 (-0.14)
Pernix Therapeutics Reports Third Quarter 2014 Financial Results and Reaffirms Guidance
Business Wire - Mon Nov 10, 7:01AM CST
--Company Reiterates Full Year 2014 and 2015 Guidance
PTX: 10.91 (-0.14)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 7.00 (+0.05), PTX: 10.91 (-0.14), AKRX: 37.00 (+1.57), RPRX: 10.10 (+0.67), NKTR: 13.91 (-0.06)
Pernix reports November 10
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 10:53AM CDT
PTX: 10.91 (-0.14)
Pernix Therapeutics to Report Q3 2014 Financial Results
Business Wire - Mon Oct 27, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that it will release its third quarter 2014 financial results on Monday, November 10, 2014 and has scheduled a conference call at 10:00 a.m. EST.
PTX: 10.91 (-0.14)
5 Stocks Under $10 Set to Soar
at The Street - Fri Oct 17, 8:41AM CDT
These under-$10 stocks look ready to trade higher from current levels.
GOMO: 6.71 (+0.71), ARWR: 6.36 (-0.17), PTX: 10.91 (-0.14), ADHD: 3.64 (+0.02), ZQK: 2.02 (-0.06), SALT: 4.22 (-0.18)
3 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 15, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HGG: 6.06 (+0.16), PTX: 10.91 (-0.14), IVAC: 7.76 (-0.12)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Sep 26, 1:16PM CDT
These under-$10 stocks look ready to trade higher from current levels.
PTX: 10.91 (-0.14), TGS: 3.62 (unch), RPRX: 10.10 (+0.67), NQ: 7.50 (-0.25), CVGI: 6.40 (-0.21)
Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.
Business Wire - Wed Aug 20, 7:01AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix first announced its agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet(R) on May 14. Pernix's expanded team of approximately 100 specialty sales professionals will support the sales and marketing of Treximet(R). The Company will hold a conference call on Wednesday, August 20 at 9:00 a.m. EDT to discuss this acquisition.
PTX: 10.91 (-0.14), GSK: 45.74 (+0.12), POZN: 9.33 (-0.06)
POZEN Announces U.S. Rights For TREXIMET(R) Have Been Acquired by Pernix Therapeutics
Business Wire - Wed Aug 20, 7:00AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the acquisition of all of GlaxoSmithKline's (GSK) rights to Treximet(R) (sumatriptan / naproxen sodium) have been acquired by Pernix Therapeutics Holdings, Inc. (Pernix). The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix have amended the agreement to address rights of the parties and future development.
PTX: 10.91 (-0.14), GSK: 45.74 (+0.12), POZN: 9.33 (-0.06)
Pernix Therapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date periods ended June 30, 2014.
PTX: 10.91 (-0.14)
Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed
PR Newswire - Thu Aug 07, 8:20AM CDT
On Wednesday, August 6, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 16,443.34, and the S&P 500 closed the day flat at 1,920.24. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, while the index has advanced 5.09% in the previous three months. Investor-Edge has initiated coverage on the following equities: Theravance Inc. (NASDAQ: THRX), Akorn Inc. (NASDAQ: AKRX), Endo International PLC (NASDAQ: ENDP), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), and Depomed Inc. (NASDAQ: DEPO). Free research on these five companies can be accessed at:
ENDP: 67.64 (-0.25), THRXV: 28.00 (+7.07), PTX: 10.91 (-0.14), AKRX: 37.00 (+1.57), DEPO: 14.76 (+0.11), THRX: 13.66 (+0.34)
Closing for Pernix Transaction to Acquire Treximet(R) Tablets for Migraine from GSK Delayed
Business Wire - Mon Aug 04, 8:15AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company" , a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue.
PTX: 10.91 (-0.14), GSK: 45.74 (+0.12)
Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014
Business Wire - Fri Jul 25, 8:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results.
PTX: 10.91 (-0.14)
PTX Recent Posts: http://investorshangout.com/Pernix-Therapeuti...PTX-57271/
PTX Pernix Therapeutics Holdings Inc. Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
PGNX: 6.50 (-0.11), ICUI: 83.66 (-1.07), CDZI: 10.71 (+0.03), INSY: 38.61 (-1.04), PCMI: 8.82 (+0.02), PTX: 10.91 (-0.14), CYAN: 6.23 (+0.25), ACHN: 13.92 (-0.93), AGIO: 87.23 (+0.36), LIOX: 5.30 (-0.13), PLNR: 6.70 (-0.45)
Midday gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:45AM CST
FSM: 4.27 (-0.21), HEAR: 4.02 (+0.01), JRJC: 6.65 (-0.55), CVO: 1.76 (-0.15), AAOI: 12.23 (-0.09), UNIS: 3.02 (-0.02), HIIQ: 8.45 (-0.25), CYAN: 6.23 (+0.25), PTX: 10.91 (-0.14), TRMR: 2.87 (-0.07), PRKR: 1.08 (unch), SUMR: 2.87 (+0.07), VSLR: 12.00 (-0.33), RVP: 4.00 (-0.10), ASCMA: 52.00 (+0.69), ICUI: 83.66 (-1.07), CALL: 8.40 (-0.28), DMD: 5.43 (-0.27), AST: 3.96 (-0.07), ASEI: 44.21 (-0.56)
Pernix Therapeutics Holdings' (PTX) CEO Douglas Drysdale on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:46PM CST
PTX: 10.91 (-0.14)
Pernix Therapeutics ups revenues 72% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:15PM CST
PTX: 10.91 (-0.14)
Pernix Therapeutics Holdings (PTX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:55AM CST
PTX: 10.91 (-0.14)
Pernix Therapeutics misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:09AM CST
PTX: 10.91 (-0.14)
Pernix Therapeutics Reports Third Quarter 2014 Financial Results and Reaffirms Guidance
Business Wire - Mon Nov 10, 7:01AM CST
--Company Reiterates Full Year 2014 and 2015 Guidance
PTX: 10.91 (-0.14)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 7.00 (+0.05), PTX: 10.91 (-0.14), AKRX: 37.00 (+1.57), RPRX: 10.10 (+0.67), NKTR: 13.91 (-0.06)
Pernix reports November 10
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 10:53AM CDT
PTX: 10.91 (-0.14)
Pernix Therapeutics to Report Q3 2014 Financial Results
Business Wire - Mon Oct 27, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that it will release its third quarter 2014 financial results on Monday, November 10, 2014 and has scheduled a conference call at 10:00 a.m. EST. PTX: 10.91 (-0.14)
5 Stocks Under $10 Set to Soar
at The Street - Fri Oct 17, 8:41AM CDT
These under-$10 stocks look ready to trade higher from current levels.
GOMO: 6.71 (+0.71), ARWR: 6.36 (-0.17), PTX: 10.91 (-0.14), ADHD: 3.64 (+0.02), ZQK: 2.02 (-0.06), SALT: 4.22 (-0.18)
3 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 15, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HGG: 6.06 (+0.16), PTX: 10.91 (-0.14), IVAC: 7.76 (-0.12)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Sep 26, 1:16PM CDT
These under-$10 stocks look ready to trade higher from current levels.
PTX: 10.91 (-0.14), TGS: 3.62 (unch), RPRX: 10.10 (+0.67), NQ: 7.50 (-0.25), CVGI: 6.40 (-0.21)
Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.
Business Wire - Wed Aug 20, 7:01AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix first announced its agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet(R) on May 14. Pernix's expanded team of approximately 100 specialty sales professionals will support the sales and marketing of Treximet(R). The Company will hold a conference call on Wednesday, August 20 at 9:00 a.m. EDT to discuss this acquisition. PTX: 10.91 (-0.14), GSK: 45.74 (+0.12), POZN: 9.33 (-0.06)
POZEN Announces U.S. Rights For TREXIMET(R) Have Been Acquired by Pernix Therapeutics
Business Wire - Wed Aug 20, 7:00AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the acquisition of all of GlaxoSmithKline's (GSK) rights to Treximet(R) (sumatriptan / naproxen sodium) have been acquired by Pernix Therapeutics Holdings, Inc. (Pernix). The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix have amended the agreement to address rights of the parties and future development.
PTX: 10.91 (-0.14), GSK: 45.74 (+0.12), POZN: 9.33 (-0.06)
Pernix Therapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date periods ended June 30, 2014. PTX: 10.91 (-0.14)
Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed
PR Newswire - Thu Aug 07, 8:20AM CDT
On Wednesday, August 6, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 16,443.34, and the S&P 500 closed the day flat at 1,920.24. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, while the index has advanced 5.09% in the previous three months. Investor-Edge has initiated coverage on the following equities: Theravance Inc. (NASDAQ: THRX), Akorn Inc. (NASDAQ: AKRX), Endo International PLC (NASDAQ: ENDP), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), and Depomed Inc. (NASDAQ: DEPO). Free research on these five companies can be accessed at:
ENDP: 67.64 (-0.25), THRXV: 28.00 (+7.07), PTX: 10.91 (-0.14), AKRX: 37.00 (+1.57), DEPO: 14.76 (+0.11), THRX: 13.66 (+0.34)
Closing for Pernix Transaction to Acquire Treximet(R) Tablets for Migraine from GSK Delayed
Business Wire - Mon Aug 04, 8:15AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue. PTX: 10.91 (-0.14), GSK: 45.74 (+0.12)
Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014
Business Wire - Fri Jul 25, 8:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results.
PTX: 10.91 (-0.14)
